Cancer vaccination therapy by using tumor-associated antigen GPC3-targeted peptide in the partients who have received trans-arterial infusion chemotherapy against advanced hepatocellular carcinoma -A randomized double blind study-

INTERVENTION: Cancer vaccination therapy by using tumor‐associated antigen GPC3‐targeted peptide in the patients who have received trans‐arterial infusion chemotherapy against advanced HCCs. Cancer vaccination therapy by using IFA in the patients who have received trans‐arterial infusion chemotherapy against advanced HCCs. CONDITION: hepatocellular carcinoma PRIMARY OUTCOME: safety SECONDARY OUTCOME: immunologicalresponse and clinical efficacy INCLUSION CRITERIA: 1. Patients who have received trans‐arterial infusion chemotherapy. 2. more than 20, less than 80 years of age. 3. Performance status (ECOG) of the patients are 0‐2. 4. Child‐Pugh class A or B. 5. Has adequate organ function as difined by following criteria. 1 WBC count more than 2000/mm3, less than 15000/mm3. 2 Plt count more than 50000/mm3. 3 AST and ALT less than 150IU/L. 4 T‐Bil less than 3.0mg/dl. 5 Creatinine less than 3.0mg/dl. 6 Patients who have HLA‐A*2402. 7 All patients gave written informed consent.